Role of Biosensing Technology for NeuroAIDS Management.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. CNS organoids: an innovative tool for neurological disease modeling and drug neurotoxicity screening.Drug discovery today · 2020
   Review
2. In-vitro blood-brain barrier models for drug screening and permeation studies: an overview.Drug design, development and therapy · 2019
   Review
3. Advancements in nano-enabled therapeutics for neuroHIV management.International journal of nanomedicine
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.